Systemic tumor necrosis factor-alpha decreases brain stimulation reward and increases metabolites of serotonin and dopamine in the nucleus accumbens of mice

Behavioural Brain Research

Volumn 253, Issue , 2013, Pages 191-195

  Van Heesch, Floor ^a   Prins, Jolanda ^a   Korte Bouws, Gerdien A H ^a   Westphal, Koen G C ^a   Lemstra, Suzanne ^a   Olivier, Berend ^a   Kraneveld, Aletta D ^a   Korte, S Mechiel ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anhedonia; Intracranial self stimulation; Microdialysis; Nucleus accumbens; Serotonin transporter; TNF

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; SEROTONIN TRANSPORTER; TUMOR NECROSIS FACTOR ALPHA;

ANHEDONIA; ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; IN VIVO STUDY; LATENT PERIOD; MALE; METABOLITE; MICRODIALYSIS; MONOAMINERGIC SYSTEM; MOUSE; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REWARD; WEIGHT REDUCTION;

5-HIAA; 5-HT; 5-HYDROXYINDOLEACETIC ACID; ANHEDONIA; DA; DAT; DIHYDROXYPHENYLACETIC ACID; DOPAC; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; HVA; ICSS; INTRACRANIAL SELF-STIMULATION; LIPOPOLYSACCHARIDE; LPS; MAJOR DEPRESSION; MD; MICRODIALYSIS; NAC; NUCLEUS ACCUMBENS; REPEATED MEASURES ANALYSIS OF VARIANCE; REPEATED MEASURES ANOVA; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SEROTONIN; SEROTONIN TRANSPORTER; SERT; SSRI; TNF-Α; TUMOR NECROSIS FACTOR-Α; VESICULAR MONOAMINE TRANSPORTER 2; VMAT-2;

3,4-DIHYDROXYPHENYLACETIC ACID; AFFECT; ANIMALS; BODY WEIGHT; BRAIN; DOPAMINE; ELECTRIC STIMULATION; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; NUCLEUS ACCUMBENS; RECOMBINANT PROTEINS; REWARD; SEROTONIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881117875     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.07.038     Document Type: Article

References (29)

1. Aaltonen K.J., Virkki L.M., Malmivaara A., Konttinen Y.T., Nordstrom D.C., Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 2012, 7:e30275.
2. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135.
3. Menter A., Gordon K.B., Leonardi C.L., Gu Y., Goldblum O.M. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology 2010, 63:448-456.
4. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
5. Uguz F., Akman C., Kucuksarac S., Tufekci O. Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry and Clinical Neurosciences 2009, 63:50-55.
6. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
7. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 2006, 59:1151-1159.
8. Chaudhury D., Walsh J.J., Friedman A.K., Juarez B., Ku S.M., Koo J.W., et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 2013, 493:532-536.
9. Tye K.M., Mirzabekov J.J., Warden M.R., Ferenczi E.A., Tsai H.C., Finkelstein J., et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-541.
10. Olds M.E. Enhanced dopamine receptor activation in accumbens and frontal cortex has opposite effects on medial forebrain bundle self-stimulation. Neuroscience 1990, 35:313-325.
11. Anisman H., Kokkinidis L., Merali Z. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Research 1996, 731:1-11.
12. Borowski T., Kokkinidis L., Merali Z., Anisman H. Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia. Neuroreport 1998, 9:3797-3802.
13. Johnson P.M., Hollander J.A., Kenny P.J. Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. Pharmacology Biochemistry and Behavior 2008, 90:409-415.
14. Caldarone B.J., Paterson N.E., Zhou J., Brunner D., Kozikowski A.P., Westphal K.G., et al. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties. Journal of Pharmacology and Experimental Therapeutics 2010, 335:762-770.
15. Prins J., Westphal K.G., Korte-Bouws G.A., Quinton M.S., Schreiber R., Olivier B., et al. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats. Pharmacology Biochemistry and Behavior 2011, 97:444-452.
16. Merali Z., Lacosta S., Anisman H. Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study. Brain Research 1997, 761:225-235.
17. Mossner R., Heils A., Stober G., Okladnova O., Daniel S., Lesch K.P. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochemistry International 1998, 33:251-254.
18. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.
19. Baganz N.L., Blakely R.D. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chemical Neuroscience 2013, 4:48-63.
20. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 2012, 62:419-426.
21. Nakajima A., Yamada K., Nagai T., Uchiyama T., Miyamoto Y., Mamiya T., et al. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. Journal of Neuroscience 2004, 24:2212-2225.
22. Lai Y.T., Tsai Y.P., Cherng C.G., Ke J.J., Ho M.C., Tsai C.W., et al. Lipopolysaccharide mitagates methamphetamine-induced striatal dopamine depletion via modulating local TNF-alpha and dopamine transporter expression. Journal of Neural Transmission 2009, 116:405-415.
23. Moron J.A., Zakharova I., Ferrer J.V., Merrill G.A., Hope B., Lafer E.M., et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. Journal of Neuroscience 2003, 23:8480-8488.
24. Wise R.A. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotoxicity Research 2008, 14:169-183.
25. Dunn A.J. Cytokine activation of the HPA axis. Annals of the New York Academy of Sciences 2000, 917:608-617.
26. Hayley S., Brebner K., Lacosta S., Merali Z., Anisman H. Sensitization to the effects of tumor necrosis factor-alpha: neuroendocrine, central monoamine, and behavioral variations. Journal of Neuroscience 1999, 19:5654-5665.
27. Lindqvist D., Janelidze S., Hagell P., Erhardt S., Samuelsson M., Minthon L., et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry 2009, 66:287-292.
28. van Heesch F., Prins J., Konsman J.P., Westphal K.G., Olivier B., Kraneveld A.D., et al. Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: an intracranial self-stimulation study. Brain, Behavior, and Immunity 2013, 29:98-103.
29. Bah T.M., Benderdour M., Kaloustian S., Karam R., Rousseau G., Godbout R. Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behavioural Brain Research 2011, 225:243-251.